Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + epirubicin
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This investigational combination therapy consists of camrelizumab (SHR-1210) and epirubicin. Camrelizumab is a humanized monoclonal antibody that targets the programmed death-1 (PD-1) receptor, acting as a checkpoint inhibitor to block the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby enhancing the body's anti-tumor immune response. Epirubicin is an anthracycline chemotherapy agent that works by intercalating into DNA and inhibiting topoisomerase II, which interferes with DNA replication and RNA synthesis in rapidly dividing cancer cells. This combination is being evaluated in Phase 2 clinical trials, specifically by Henan Cancer Hospital, as a second-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) who have failed prior first-line therapies.
- Other names
- camrelizumab plus epirubicinSHR-1210 plus epirubicinSHR1210 plus epirubicinSHR 1210 plus epirubicinEpirubicin plus SHR1210
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on camrelizumab + epirubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + epirubicin.